Tribute Pharmaceuticals Canada Inc (SLRXF) financial statements (2021 and earlier)

Company profile

Business Address 544 EGERTON ST
LONDON, ON N5W 3Z8
State of Incorp. ON
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2014
12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments432
Cash and cash equivalents432
Receivables211
Inventory, net of allowances, customer advances and progress billings111
Inventory111
Prepaid expense00
Deferred costs00 
Prepaid expense and other current assets0
Other undisclosed current assets010
Total current assets:755
Noncurrent Assets
Property, plant and equipment111
Intangible assets, net (including goodwill)451314
Goodwill444
Intangible assets, net (excluding goodwill)411011
Other undisclosed noncurrent assets000
Total noncurrent assets:461516
TOTAL ASSETS:532021
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:435
Other undisclosed accounts payable and accrued liabilities435
Debt101
Derivative instruments and hedges, liabilities330
Other undisclosed current liabilities 0(0)
Total current liabilities:967
Noncurrent Liabilities
Long-term debt and lease obligation1462
Long-term debt, excluding current maturities1462
Liabilities, other than long-term debt  0
Deferred tax liabilities, net  0
Other undisclosed noncurrent liabilities  0
Total noncurrent liabilities:1462
Total liabilities:23129
Stockholders' equity
Stockholders' equity attributable to parent30812
Common stock412018
Additional paid in capital322
Accumulated other comprehensive loss (0) 
Accumulated deficit(20)(14)(8)
Warrants and rights outstanding6  
Total stockholders' equity:30812
TOTAL LIABILITIES AND EQUITY:532021

Income statement (P&L) ($ in millions)

12/31/2014
12/31/2013
12/31/2012
Revenues171312
Revenue, net171412
Cost of revenue
(Cost of Goods and Services Sold)
(2)(2)(1)
Other undisclosed gross profit(6)(6)(6)
Gross profit:965
Operating expenses(12)(11)(10)
Operating loss:(3)(5)(4)
Nonoperating income (expense)
(Investment Income, Nonoperating)
(0)(0)0
Interest and debt expense(1)(1)(0)
Net loss:(4)(6)(4)
Other undisclosed net income (loss) attributable to parent(1)(1)1
Net loss available to common stockholders, diluted:(6)(7)(3)

Comprehensive Income ($ in millions)

12/31/2014
12/31/2013
12/31/2012
Net loss:(4)(6)(4)
Comprehensive loss:(4)(6)(4)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(1)(1)1
Comprehensive loss, net of tax, attributable to parent:(6)(7)(3)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: